ArticleMolecular medicine (Cambridge, Mass.)2026
Complement protein C1q induces endothelial apoptosis through C1qBP regulation of mitochondrial function in lung endothelial cells in systemic sclerosis.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSystemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy and fibrosis, with pulmonary complications as the leading cause of mortality. Although abnormal activation of the complement system is implicated in SSc pathogenesis, the role of complement protein C1q in pulmonary endothelial injury remains unclear.
methodsIn this study, we employed a bleomycin (BLM)-induced SSc mouse model and cultured lung microvascular endothelial cells to investigate the effect of C1q on mitochondrial function and endothelial apoptosis. We further investigated the involvement of complement component 1q subcomponent-binding protein (C1qBP) in this process. We performed immunohistochemistry, Western blotting, immunoprecipitation, mitochondrial function assays, and flow cytometry to assess protein expression, mitochondrial integrity, and apoptotic responses.
resultsExpression of C1q and C1qBP was significantly elevated in the SSc model group, accompanied by translocation of prohibitin 2 (PHB2) from the mitochondria to the cytoplasm, loss of mitochondrial membrane potential, reduced ATP synthesis, and increased apoptosis. Knockdown of C1qBP inhibited PHB2 translocation, improved mitochondrial function, reduced endothelial apoptosis, and attenuated lung fibrosis.
conclusionC1q regulates the mitochondrial localization of PHB2 via C1qBP, inducing mitochondrial dysfunction and endothelial apoptosis, thereby contributing to SSc-associated lung injury. Targeting the C1q-C1qBP-PHB2 axis may provide a new therapeutic strategy for SSc.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.